Immunity against Mycobacterium tuberculosis and the risk of biologic anti-TNF-α reagents

Pediatric Rheumatology

Volumn 12, Issue 1, 2014, Pages

  Yasui, Kozo ^a,b  

^a HIROSHIMA CITY HOSPITAL   (Japan)

^b OKAYAMA UNIVERSITY   (Japan)

Author keywords

Dissemination; Granulomatous infection; Inflammatory bowel disease (IBD); Juvenile idiopathic arthritis (JIA); Latency; Rheumatoid arthritis (RA); Tuberculosis (TB); Tumor necrosis factor (TNF )

Indexed keywords

ADALIMUMAB; BIOLOGICAL FACTOR; GAMMA INTERFERON; INFLIXIMAB; REACTIVE NITROGEN SPECIES; SUPEROXIDE; TUMOR NECROSIS FACTOR ALPHA CONVERTING ENZYME; TUMOR NECROSIS FACTOR RECEPTOR 1; TUMOR NECROSIS FACTOR RECEPTOR 2; VACCINE; BIOLOGICAL PRODUCT; TUMOR NECROSIS FACTOR ALPHA;

CD8+ T LYMPHOCYTE; DENDRITIC CELL; DRUG MECHANISM; GRANULOMA; HUMAN; INFECTION RISK; INNATE IMMUNITY; JUVENILE RHEUMATOID ARTHRITIS; LUNG ALVEOLUS EPITHELIUM; LUNG ALVEOLUS MACROPHAGE; MILIARY TUBERCULOSIS; MUCOCUTANEOUS LYMPH NODE SYNDROME; MYCOSIS; NONHUMAN; PATHOPHYSIOLOGY; PATIENT CARE; POSTPRIMARY TUBERCULOSIS; PROGNOSIS; REVIEW; RHEUMATOID ARTHRITIS; RISK FACTOR; TUBERCULOSIS; VIRUS INFECTION; ANTAGONISTS AND INHIBITORS; BACTERIAL INFECTIONS; IMMUNOLOGY; MYCOBACTERIUM TUBERCULOSIS; MYCOSES; RHEUMATIC DISEASES; VIRUS DISEASES;

BACTERIAL INFECTIONS; BIOLOGICAL PRODUCTS; HUMANS; IMMUNITY, INNATE; MYCOBACTERIUM TUBERCULOSIS; MYCOSES; RHEUMATIC DISEASES; RISK FACTORS; TUBERCULOSIS; TUMOR NECROSIS FACTOR-ALPHA; VIRUS DISEASES;

EID: 84910056936     PISSN: None     EISSN: 15460096     Source Type: Journal    
DOI: 10.1186/1546-0096-12-45     Document Type: Review

References (42)

1. Keane J, Gershon S, Wise RP, Mirabile-Levens E, Kasznica J, Schwieterman WD, Siegel JN, Braun MM. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 2001, 345:1098-1104. 10.1056/NEJMoa011110, 11596589.
2. Gardam MA, Keystone EC, Menzies R, Manners S, Skamene E, Long R, Vinh DC. Anti-tumour necrosis factor agents and tuberculosis risk: mechanisms of action and clinical management. Lancet Infect Dis 2003, 3:148-155. 10.1016/S1473-3099(03)00545-0, 12614731.
3. Askling J, Fored CM, Brandt L, Baecklund E, Bertilsson L, Cöster L, Geborek P, Jacobsson LT, Lindblad S, Lysholm J, Rantapää-Dahlqvist S, Saxne T, Romanus V, Klareskog L, Feltelius N. Risk and case characteristics of tuberculosis in rheumatoid arthritis associated with tumor necrosis factor antagonists in Sweden. Arthritis Rheum 2005, 52:1986-1992. 10.1002/art.21137, 15986370.
4. Wallis RS. Tumour necrosis factor antagonists: structure, function, and tuberculosis risks. Lancet Infect Dis 2008, 8:601-611. 10.1016/S1473-3099(08)70227-5, 18922482.
5. Wong M, Ziring D, Korin Y, Desai S, Kim S, Lin J, Gjertson D, Braun J, Reed E, Singh RR. TNFα blockade in human diseases: mechanisms and future directions. Clin Immunol 2008, 126:121-136. 10.1016/j.clim.2007.08.013, 2291518, 17916444.
6. Martin-Mola E, Balsa A. Infectious complications of biologic agents. Rheum Dis Clin North Am 2009, 35:183-199. 10.1016/j.rdc.2009.03.009, 19481004.
7. World Health Organization Global Tuberculosis Report 2013, Geneva: WHO, http://www.who.int/tb/publications/global_report/en/.
8. Nardell EA, Wallis RS. Here today - gone tomorrow: the case for transient acute tuberculosis infection. Am J Respir Crit Care Med 2006, 174:734-735. 10.1164/rccm.200607-923ED, 16988164.
9. Aoki K, Matsumoto S, Hirayama Y, Wada T, Ozeki Y, Niki M, Domenech P, Umemori K, Yamamoto S, Mineda A, Matsumoto M, Kobayashi K. Extracellular mycobacterial DNA-binding protein 1 participates in Mycobacterium-lung epithelial cell interaction through hyaluronic acid. J Biol Chem 2004, 279:39798-39806. 10.1074/jbc.M402677200, 15234978.
10. Kohwiwattanagun J, Kawamura I, Fujimura T, Mitsuyam AM. Mycobacterial mammalian cell entry protein 1a (Mce1A)-mediated adherence enhances the chemokine production by A549 alveolar epithelial cells. Microbiol Immunol 2007, 51:253-261. 10.1111/j.1348-0421.2007.tb03897.x, 17310094.
11. Jozefowski S, Marcinkiewicz J. Aggregates of denatured proteins stimulate nitric oxide and superoxide production in macrophages. Inflamm Res 2010, 59:277-289. 10.1007/s00011-009-0096-5, 19784549.
12. Liu PT, Stenger S, Li II, Wenzel L, Tan BH, Krutzik SR, Ochoa MT, Schauber J, Wu K, Meinken C, Kamen DL, Wagner M, Bals R, Steinmeyer A, Zügel U, Gallo RL, Eisenberg D, Hewison M, Hollis BW, Adams JS, Bloom BR, Modlin RL. Toll-like receptor triggering of a vitamin D-mediated human antimicrobial response. Science 2006, 311:1770-1773. 10.1126/science.1123933, 16497887.
13. Yang CS, Shin DM, Kim KII, Lee ZW, Lee CH, Park SG, Bae YS, Jo EK. NADPH oxidase 2 interaction with TLR2 is required for efficient innate immune responses to mycobacteria via cathelicidin expression. J Immunol 2009, 182:3696-3705. 10.4049/jimmunol.0802217, 19265148.
14. Kusunose E, Ichihara K, Noda Y, Kusunose M. Superoxide dismutase from Mycobacterium tuberculosis. J Biochem 1976, 80:1343-1352.
15. Casbon AJ, Long ME, Dunn KW, Allen LA, Dinauer MC. Effects of IFN-γ on intracellular trafficking and activity of macrophage NADPH oxidase flavocytochrome b558. J Leukoc Biol 2012, 92:869-882. 10.1189/jlb.0512244, 3441311, 22822009.
16. Roach DR, Bean AG, Demangel C, France MP, Briscoe H, Britton WJ. TNF regulates chemokine induction essential for cell recruitment, granuloma formation, and clearance of mycobacterial infection. J Immunol 2002, 168:4620-4627. 10.4049/jimmunol.168.9.4620, 11971010.
17. Stenger S. Immunological control of tuberculosis: role of tumor necrosis factor and more. Ann Rheum Dis 2005, 64:iv24-iv28. 1766911, 16239381.
18. Mulligan MS, Vaporciyan AA, Miyasaka M, Tamatani T, Ward PA. Tumor necrosis factor alpha regulates in vivo intrapulmonary expression of ICAM-1. Am J Pathol 1993, 142:1739-1749. 1886993, 7685152.
19. Stenger S, Hanson DA, Teitelbaum R, Dewan P, Niazi KR, Froelich CJ, Ganz T, Thoma-Uszynski S, Melián A, Bogdan C, Porcelli SA, Bloom BR, Krensky AM, Modlin RL. An antimicrobial activity of cytolytic T cells mediated by granulysin. Science 1998, 282:121-125.
20. Gautam US, Mehra S, Ahsan MH, Alvarez X, Niu T, Kaushal D. Role of TNF in the altered interaction of dormant mycobacterium tuberculosis with host macrophages. PLoS One 2014, 9:e95220. 10.1371/journal.pone.0095220, 3990579, 24743303.
21. Uehira K, Amakawa R, Ito T, Tajima K, Naitoh S, Ozaki Y, Shimizu T, Yamaguchi K, Uemura Y, Kitajima H, Yonezu S, Fukuhara S. Dendritic cells are decreased in blood and accumulated in granuloma in tuberculosis. Clin Immunol 2002, 105:296-303. 10.1006/clim.2002.5287, 12498811.
22. Rich EA, Tweardy DJ, Fujiwara H, Ellner JJ. Spectrum of immunoregulatory functions and properties of human alveolar macrophages. Am Rev Respir Dis 1987, 136:258-265. 10.1164/ajrccm/136.2.258, 2956914.
23. Bilyk N, Holt PG. Cytokine modulation of the immunosuppressive phenotype of pulmonary alveolar macrophage populations. Immunology 1995, 86:231-237. 1384000, 7490123.
24. Feng CG, Demangel C, Kamath AT, Macdonald M, Britton WJ. Dendritic cells infected with Mycocbacterium bovis bacillus Calmette Guerin activate CD8(+) T cells with specificity for a novel mycobacterial epitope. Int Immunol 2001, 13:451-458. 10.1093/intimm/13.4.451, 11282984.
25. Kindler V, Sappino AP, Grau GE, Piguet PF, Vassalli P. The inducing role of tumor necrosis factor in the development of bactericidal granulomas during BCG infection. Cell 1989, 56:731-740. 10.1016/0092-8674(89)90676-4, 2647299.
26. Yasui K, Yashiro M, Tsuge M, Kondo Y, Saito Y, Nagaoka Y, Yamashita N, Morishima T. Tumor necrosis factor-α can induce Langerhans-type multinucleated giant cell formation derived from myeloid dendritic cells. Microbiol Immunol 2011, 55:809-816. 10.1111/j.1348-0421.2011.00380.x, 21851385.
27. Doran MF, Crowson CS, Pond GR, O'Fallon WM, Gabriel SE. Frequency of infection in patients with rheumatoid arthritis compared with controls: a population-based study. Arthritis Rheum 2002, 46:2287-2297. 10.1002/art.10524, 12355475.
28. Seong SS, Choi CB, Woo JH, Bae KW, Joung CL, Uhm WS, Kim TH, Jun JB, Yoo DH, Lee JT, Bae SC. Incidence of tuberculosis in Korean patients with rheumatoid arthritis (RA): effects of RA itself and of tumor necrosis factor blockers. J Rheumatol 2007, 34:706-711.
29. Gomez-Reino JJ, Carmona L, Angel DM. Risk of tuberculosis in patients treated with tumor necrosis factor antagonists due to incomplete prevention of reactivation of latent infection. Arthritis Rheum 2007, 57:756-761. 10.1002/art.22768, 17530674.
30. Wallis RS, Broder MS, Wong J, Beenhouwer D. Granulomatous infectious diseases associated with tumor necrosis factor antagonists. Clin Infect Dis 2004, 38(9):1261-1265. 10.1086/383317, 15127338.
31. Ulrichs T, Kaufmann SH. New insights into the function of granulomas in human tuberculosis. J Pathol 2006, 208:261-269. 10.1002/path.1906, 16362982.
32. Peschon JJ, Torrance DS, Stocking KL, Glaccum MB, Otten C, Willis CR, Charrier K, Morrissey PJ, Ware CB, Mohler KM. TNF receptor-deficient mice reveal divergent roles for p55 and p75 in several models of inflammation. J Immunol 1998, 160:943-952.
33. Bopst M, Garcia I, Guler R, Olleros ML, Rülicke T, Müller M, Wyss S, Frei K, Le Hir M, Eugster HP. Differential effects of TNF and LTalpha in the host against M bovis BCG. Eur J Immunol 2001, 31:1935-1943. 10.1002/1521-4141(200106)31:6<1935::AID-IMMU1935>3.0.CO;2-N, 11433391.
34. Jacobs M, Brown N, Allie N, Ryffel B. Fatal Mycobacterium bovis BCG infection in TNF-LT-alpha-deficient mice. Clin Immunol 2000, 94:192-199. 10.1006/clim.2000.4835, 10692238.
35. Jacobs M, Brown N, Allie N, Chetty K, Ryffel B. Tumor necrosis factor receptor 2 plays a minoir role for mycobacterial immunity. Pathobiology 2000, 68:68-75. 10.1159/000028116, 10878503.
36. Bean AG, Roach DR, Briscoe H, France MP, Korner H, Sedgwick JD, Britton WJ. Structural deficiencies in granuloma formation in TNF gene targeted mice underlie the heightened susceptibility to aerosol Mycobacterium tuberculosis infection, which is not compensated for by lymphotoxin. J Immunol 1999, 162:3504-3511.
37. Saunders BM, Tran S, Ruuls S, Sedgwick JD, Briscoe H, Britton WJ. Transmembrane TNF is sufficient to initiate cell migration and granuloma formation and provide acute, but not long-term, control of Mycobacterium tuberculosis infection. J Immunol 2005, 174:4852-4859. 10.4049/jimmunol.174.8.4852, 15814712.
38. Fucht DM, Holland SM. Defective monocyte costimulation for IFN-γ production in familial disseminated Mycobacterium avium complex infection: abnormal IL-12 regulation. J Immunol 1996, 157:411-416.
39. Rosenzweig SD, Holland SM. Defects in the interferon-γ and interleukin-12 pathways. Immunol Rev 2005, 203:38-47. 10.1111/j.0105-2896.2005.00227.x, 15661020.
40. Mori M, Imagawa T, Hara R, Kikuchi M, Hara T, Nozawa T, Miyamae T, Yokota S. Efficacy and limitation of infliximab treatment for children with Kawasaki disease intractable to intravenous immunoglobulin therapy: report of an open-label case series. J Rheumatol 2012, 39:864-867. 10.3899/jrheum.110877, 22337241.
41. Tremoulet AH, Jain S, Jaggi P, Jimenez-Fernandez S, Pancheri JM, Sun X, Kanegaye JT, Kovalchin JP, Printz BF, Ramilo O, Burns JC. Infliximab for intensification of primary therapy for Kawasaki disease: a phase 3 randomised, double-blind, placebo-controlled trial. Lancet 2014, 383:1731-1738. 10.1016/S0140-6736(13)62298-9, 24572997.
42. Roy A, Eisenhut M, Harris RJ, Rodrigues LC, Sridhar S, Habermann S, Snell L, Mangtani P, Adetifa I, Lalvani A, Abubakar I. Effect of BCG vaccination against Mycobacterium tuberculosis infection in children: systemic review and meta-analysis. Br Med J 2014, 349:g4643.